Last updated: July 22, 2026
Litigation summary and analysis for Neos Therapeutics, Inc. v. Actavis Laboratories FL, Inc. (1:16-cv-00766)
Executive summary
Neos Therapeutics, Inc. sued Actavis Laboratories FL, Inc. in the U.S. District Court for the District of New Jersey under the Hatch-Waxman framework in case 1:16-cv-00766. The dispute centers on an ANDA generic challenge to an Neos-listed branded drug and requires resolving patent validity and infringement tied to the FDA regulatory filing. The litigation posture is best summarized as a Paragraph IV-style patent infringement action with adjudication focused on whether Actavis’s ANDA product would infringe one or more asserted Orange Book patents and whether those patents are enforceable.
Court and docket: U.S. District Court, District of New Jersey; Civil Action No. 1:16-cv-00766.
Parties: Neos Therapeutics, Inc. (plaintiff) and Actavis Laboratories FL, Inc. (defendant).
IP posture: ANDA-based patent infringement litigation (Hatch-Waxman).
What is the case background for Neos Therapeutics, Inc. v. Actavis Laboratories FL, Inc. (1:16-cv-00766)?
Case identity. The matter is docketed as 1:16-cv-00766 in the District of New Jersey and lists Neos Therapeutics, Inc. as plaintiff and Actavis Laboratories FL, Inc. as defendant.
Why these suits are filed. In Hatch-Waxman cases, plaintiffs typically assert that the generic defendant’s ANDA submission constitutes an act of infringement under 35 U.S.C. §271(e)(2) by seeking FDA approval before expiration of the relevant patents listed in the Orange Book for the branded reference product.
Core litigation issues in this type of filing.
- Whether the asserted claims are infringed by the generic’s proposed ANDA product.
- Whether the asserted claims are invalid (common grounds: anticipation, obviousness, lack of written description, enablement, indefiniteness, or improper claim scope).
- Whether any jurisdictional or procedural defenses bar relief (timing, standing, patent-owner identification, and notice mechanics under 21 U.S.C. §355(j)).
- Whether any final disposition includes a settlement-driven entry date or later dismissal after claim construction or summary judgment.
What patents were asserted in 1:16-cv-00766?
No complete, case-specific patent list (patent numbers, asserted claims, or Orange Book mapping) is provided in the prompt content. Without the asserted patent bundle and claim set, a definitive infringement/validity breakdown cannot be produced in a way that is accurate to this docket.
What was the procedural timeline in Neos v. Actavis (1:16-cv-00766)?
No docket-level milestones (complaint filing date, answer date, claim construction orders, summary judgment filings, trial dates, or dispositive motions outcomes) are provided in the prompt content. Without those dates and event outcomes, timeline-based exclusivity or risk analysis cannot be tied to this specific record.
How does this case fit the Orange Book and Hatch-Waxman framework?
Hatch-Waxman structure. The case format matches the typical Paragraph IV playbook where:
- The branded manufacturer lists patents in the Orange Book for its NDA.
- The generic files an ANDA and includes certifications to each listed patent (e.g., Paragraph IV for at least one patent).
- The branded patentee sues within the statutory window, triggering an automatic stay of FDA approval if all statutory prerequisites are met (subject to the interaction with court rulings on validity/infringement).
Implication for business planning. The operative question for exclusivity, market entry timing, and non-infringement/invalidity leverage is the set of patents that were asserted and which of those patents survived dispositive motion practice. That linkage requires the specific patent numbers and the results in the record.
What did Neos claim about infringement by Actavis?
No claim chart details, infringement theories, product description of the ANDA proposed formulation/dosage form, or Markman claim construction findings are present in the provided prompt content. A true infringement analysis requires:
- the asserted claims and their constructions,
- the generic’s technical description (as pleaded and/or from ANDA-specific exhibits),
- and the court’s legal standards applied post-construction.
What were Actavis’s invalidity and non-infringement defenses?
No information is provided on which invalidity theories were raised (e.g., anticipation/obviousness, doctrine of equivalents, indefiniteness, written description/enablement) or on any claim construction and expert testimony results in the docket.
How strong is the patent estate based on this litigation?
A litigation-strength assessment depends on outcomes such as:
- denial or grant of summary judgment on infringement/invalidity,
- final judgment on one or more asserted patents,
- dismissal without prejudice with no merits ruling,
- or settlement with a stipulated dismissal and entry date.
No disposition details are provided, so the relative strength cannot be quantified.
Did the case resolve by settlement or final judgment?
No settlement terms, dismissal order, consent judgment, or final verdict details are included in the prompt content. Without final outcome information, the decision-tree for generic launch risk versus re-filing or continued litigation cannot be completed for this docket.
What does this mean for generic entry risk?
Generic entry risk is a function of:
- whether an injunction issued or stayed approval remained in effect,
- whether the asserted patents were invalidated or found not infringed,
- whether a settlement authorized a stipulated launch date,
- and whether any residual patents or continuation applications remain.
Because the prompt includes no outcome or patent list, the launch-risk conclusion for Actavis cannot be tied to the actual adjudication in 1:16-cv-00766.
Key takeaways
- Neos Therapeutics, Inc. sued Actavis Laboratories FL, Inc. in D.N.J. under case 1:16-cv-00766, consistent with an ANDA-driven patent infringement action under Hatch-Waxman.
- The litigation’s business impact depends on which Orange Book patents were asserted and what the court ultimately decided (or whether the parties settled).
- The prompt content does not include those dispositive elements, so a docket-accurate infringement/validity and entry-timing analysis cannot be produced here.
FAQs
-
What type of Hatch-Waxman case is 1:16-cv-00766?
It is an ANDA-based patent infringement action filed by the branded company against the generic defendant in the District of New Jersey.
-
Does the case involve Paragraph IV certifications?
The filing pattern matches standard Paragraph IV litigation structure, but the specific certification and patent mapping are not included in the prompt.
-
Can I determine generic launch timing from this case number alone?
Launch timing requires the docket disposition (final judgment or settlement) and any related FDA entry authorization terms, which are not included in the prompt.
-
What is the role of claim construction in these disputes?
Claim construction typically drives infringement analysis because infringement depends on the court’s interpretation of claim terms, but the claim construction results are not included in the prompt.
-
What would indicate the patent estate was weakened or strengthened?
Dispositive rulings (summary judgment invalidity or non-infringement) or a final judgment finding the asserted claims invalid or infringed would drive that assessment; outcome details are not included in the prompt.
References
- U.S. District Court for the District of New Jersey, Neos Therapeutics, Inc. v. Actavis Laboratories FL, Inc., Civil Action No. 1:16-cv-00766.
